A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins
Authors:
Open Access
- 26 November 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 103 (2) , 277-282
Abstract
One of the problems associated with the administration of immunotoxins is hypersensitivity reaction such as vascular leak syndrome. This may be prevented by decreasing the plasma half‐life. To improve immunotoxins with respect to reduced side effects, we have previously described the development of a cleavable adapter. This adapter links the toxic moiety and ligand that are usually directly coupled. In our study, the cytotoxicity of saporin linked either directly or via the adapter to epidermal growth factor (EGF) was evaluated in vitro. The immunotoxins exhibited similar cytotoxic activity towards A‐431 and HER14 cells (IC50 < 10 nM). The supernatant from 6 hr cultures of HER14 cells incubated in the presence of the adapter‐containing immunotoxin exhibited a significantly reduced cytotoxicity as compared to the directly coupled immunotoxin. Western blotting revealed that the adapter was cleaved, thus supporting our proposal that cleavable adapters may reduce nonspecific effects. A similar reduced half‐life was detected in platelet‐poor plasma. In contrast MCF‐7 cells remain unaffected by the immunotoxins. This was shown to be due to the absence of detectable EGF‐receptor in comparison to A‐431 and HER14 cells as determined by Western blotting. Furthermore, we could show that the adapter does not exert an effect on the N‐glycosidase activity of saporin. These results suggest that the use of cleavable adapters may be a useful tool in immunotoxins for reducing the killing of surrounding noncancerous cells due to nonspecific binding.Keywords
This publication has 21 references indexed in Scilit:
- Development of a novel molecular adapter for the optimization of immunotoxinsJournal of Controlled Release, 2001
- Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin bCancer Letters, 2001
- Drug targetingEuropean Journal of Pharmaceutical Sciences, 2000
- In vitro anti‐tumour activity of anti‐CD80 and anti‐CD86 immunotoxins containing type 1 ribosome‐inactivating proteinsBritish Journal of Haematology, 2000
- Apoptosis induced by immunotoxins used in the treatment of hematologic malignanciesInternational Journal of Cancer, 2000
- Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivoMolecular Medicine, 2000
- FDA Approves Fusion Protein for Treatment of LymphomaJournal of the American Pharmaceutical Association, 1999
- Targeting tumor cellsvia EGF receptors: Selective toxicity of an HBEGF-toxin fusion proteinInternational Journal of Cancer, 1998
- Induction of apoptosis by ribosome-inactivating proteins and related immunotoxinsInternational Journal of Cancer, 1996
- Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity.Proceedings of the National Academy of Sciences, 1990